Novel therapeutics in hypertriglyceridaemia and chylomicronaemia

Abstract

Currently there is evidence on hypertriglyceridaemia as an independent risk factor of atherosclerosis. Chylomicronaemia associated with very high concentration of triglycerides may cause severe and recurrent acute pancreatitis. The cause of most cases is a combination of a polygenetic basis with some lifestyles and pathological conditions. Some rare and familial chylomicronaemias are mendelian diseases with an autosomal recessive pattern. On the other hand, plasma triglycerides have considerable biological variability and usually descend with non-pharmacological interventions alone. In some cases, drugs are also required for their control, but their impact on vascular risk reduction or pancreatitis prevention is more controversial. The recent advances in knowledge of molecular lipid metabolism and pharmacological technologies are resulting in the development of new therapeutic strategies, which can be applied to patients with refractory hypertrigliceridaemia. The challenge may be how the health systems can cover its high costs.

Keywords: Anticuerpos monoclonales; Antisense oligonucleotides; Chylomicronaemia; Dislipemia genética; Gene therapy; Genetic dyslipidaemia; Hiperquilomicronemia; Hipertrigliceridemia; Hyperlipidaemic pancreatitis; Hypertriglyceridaemia; Lipid metabolism; Metabolismo lipídico; Monoclonal antibodies; Novel therapeutics; Nuevos tratamientos; Oligonucleótidos antisentido; Pancreatitis lipémica; Terapia génica.